*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.
Thermo Fisher (TMO) is poised to report its earnings on October 22, and all eyes are on its ability to sustain the robust growth trajectory it has demonstrated in recent quarters. With a market capitalization of approximately $198 billion, the company is a heavyweight in the life sciences sector, and analysts are keenly watching its performance amid a backdrop of increasing demand for its innovative solutions. The EPS estimate stands at $5.50, with a revenue projection of $10.91 billion, but the whisper number suggests a slightly more optimistic EPS of $5.61, indicating that market sentiment leans towards an expectation of outperformance. As Thermo Fisher continues to leverage its strategic acquisitions and expand its product offerings, investors will be particularly interested in how these efforts translate into financial results, especially in a competitive landscape where maintaining momentum is key.
Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.
Website: https://www.thermofisher.com
Average Sentiment Score:
Overall Sentiment: